REQUEST A DEMO
Total
USD $0.00
Search more companies

Aptamer Sciences Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Aptamer Sciences Inc. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The Company provides services include aptamer synthesis and aptamer discovery. The Company also develops biopharmaceuticals such as insulin substitutes, insulin sensitizers, and liver cancer drugs. In addition, the Company also produces lung cancer diagnostic kits. The Company was established on April 1, 2011. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on September 16, 2020.

Headquarters
3-301, (Sampyeong-Dong Pangyo Seven Venture Valley1), 15, Pangyo-Ro 228Beon-Gil, Bundang-Gu
Seongnam; Gyeonggi;

Contact Details: Purchase the Aptamer Sciences Inc. report to view the information.

Website: http://www.aptsci.com

Basic Information
Total Employees:
Purchase the Aptamer Sciences Inc. report to view the information.
Outstanding Shares:
Purchase the Aptamer Sciences Inc. report to view the information.
Registered Capital:
Purchase the Aptamer Sciences Inc. report to view the information.
Financial Auditors:
Purchase the Aptamer Sciences Inc. report to view the information.
Incorporation Date:
April 01, 2011
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
㈜압타머사이언스
Company Performance
Financial values in the chart are available after Aptamer Sciences Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-31.05%
Total operating revenue
-31.06%
Operating profit (EBIT)
46.93%
EBITDA
48.75%
Net Profit (Loss) for the Period
21.94%
Total assets
-17.25%
Total equity
-55.21%
Operating Profit Margin (ROS)
1528.23%
Net Profit Margin
-918.14%
Return on Equity (ROE)
-24.26%
Debt to Equity Ratio
64.72%
Quick Ratio
-47.01%
Cash Ratio
-2.36%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?